Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables

Erhart F1,2, Buchroithner J3, Reitermaier R4, Fischhuber K4, Klingenbrunner S4, Sloma I5, Hibsh D5, Kozol R5, Efroni S5, Ricken G6, Wöhrer A6, Haberler C6, Hainfellner J6, Krumpl G4, Felzmann T4, Dohnal AM7, Marosi C8, Visus C4 1-Institute of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria. friedrich.erhart@meduniwien.ac.at. 2-Department of Neurosurgery, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria. friedrich.erhart@meduniwien.ac.at. 3-University Clinic for Neurosurgery, Kepler University Hospital, Johannes Kepler University, Wagner-Jauregg-Weg 15, 4020, Linz, Austria. 4-Activartis Biotech GmbH, Wilhelminenstraße 91/IIf, 1160, Vienna, Austria. 5-Systems Bio Medicine Lab, Bar Ilan University, 5290002, Ramat Gan, Israel. 6-Institute of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria. 7-Laboratory for Tumor Immunology, CCRI St. Anna Kinderkrebsforschung, Zimmermannplatz 10, 1090, Vienna, Austria. 8-Clinical Division of Medical Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1097, Vienna, Austria.